Editas Medicine, Inc. (EDIT)
2.40
-0.09
(-3.61%)
USD |
NASDAQ |
Oct 23, 16:00
2.385
-0.02
(-0.62%)
After-Hours: 20:00
Editas Medicine Price to Book Value : 3.500 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.500 |
| October 22, 2026 | 3.631 |
| October 21, 2026 | 3.660 |
| October 20, 2026 | 3.762 |
| October 19, 2026 | 3.529 |
| October 16, 2026 | 3.427 |
| October 15, 2026 | 3.558 |
| October 14, 2026 | 3.310 |
| October 13, 2026 | 3.566 |
| October 12, 2026 | 4.010 |
| October 09, 2026 | 4.229 |
| October 08, 2026 | 4.142 |
| October 07, 2026 | 4.010 |
| October 06, 2026 | 3.981 |
| October 05, 2026 | 4.069 |
| October 02, 2026 | 3.821 |
| October 01, 2026 | 3.675 |
| September 30, 2026 | 3.748 |
| September 29, 2026 | 3.777 |
| September 28, 2026 | 3.660 |
| September 25, 2026 | 3.762 |
| September 24, 2026 | 4.010 |
| September 23, 2026 | 3.923 |
| September 22, 2026 | 4.258 |
| September 21, 2026 | 4.127 |
| Date | Value |
|---|---|
| September 18, 2026 | 3.937 |
| September 17, 2026 | 3.967 |
| September 16, 2026 | 3.952 |
| September 15, 2026 | 3.835 |
| September 14, 2026 | 3.996 |
| September 11, 2026 | 3.937 |
| September 10, 2026 | 3.864 |
| September 09, 2026 | 4.040 |
| September 08, 2026 | 4.419 |
| September 04, 2026 | 4.710 |
| September 03, 2026 | 4.492 |
| September 02, 2026 | 4.492 |
| September 01, 2026 | 4.477 |
| August 31, 2026 | 4.462 |
| August 28, 2026 | 4.608 |
| August 27, 2026 | 4.812 |
| August 26, 2026 | 4.637 |
| August 25, 2026 | 4.783 |
| August 24, 2026 | 4.375 |
| August 21, 2026 | 4.535 |
| August 20, 2026 | 4.287 |
| August 19, 2026 | 4.740 |
| August 18, 2026 | 4.200 |
| August 17, 2026 | 4.142 |
| August 14, 2026 | 4.112 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Recursion Pharmaceuticals, Inc. | 2.160 |
| Alnylam Pharmaceuticals, Inc. | 22.13 |
| Geron Corp. | 3.292 |
| Halozyme Therapeutics, Inc. | 99.81 |
| Novavax, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 5.164 |
| Price | 2.40 |
| Earnings Yield | -31.02% |
| Market Cap | 368.47M |